This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Is Rescheduling a Certainty for Cannabis? ETFs That Surge
by Sanghamitra Saha
In a White House meeting, Vice President Kamala Harris this week urged the DEA to expedite the rescheduling of marijuana. President Biden also lately talked about ongoing efforts to review the federal classification of marijuana, hinting at his commitment to potential reforms
Cannabis ETFs Outperform in January
by Sweta Killa
The cannabis industry has been performing well this year after the US Drug Enforcement Administration started reviewing the potential reclassification of cannabis from Schedule I to Schedule III.
Cannabis ETFs Spike on Marijuana Classification Review
by Sweta Killa
Marijuana stocks spiked following the report that the US Drug Enforcement Administration (¿¿¿DEA¿¿¿) is reviewing the potential reclassification of cannabis from Schedule I to Schedule III.
Behind the Recent Surge in Marijuana ETFs
by Sanghamitra Saha
In a significant development, the Department of Health and Human Services (HHS) has recently initiated a review of marijuana's classification under the Controlled Substances Act.
Cannabis Stocks Are Moving Higher
by Brian Bolan
A looking into what is driving the recent spike in cannabis stocks.
Cannabis ETFs Soar on Hopes of Federal Legalization
by Sweta Killa
Marijuana stocks have been surging following a proposal by the Drug Enforcement Agency (???DEA???) to reclassify cannabis as a substance with reduced risk, fueling anticipation of federal legalization.
Cannabis ETFs Surge on Legalization Hopes: More Run Ahead?
by Sanghamitra Saha
The prospect of marijuana reclassification has injected newfound optimism into the cannabis investment landscape.
SAFE Banking Act Resurgence Boosts Pot ETFs: A New Era Ahead?
by Sanghamitra Saha
A fresh wave of investment opportunities emerges as the SAFE Banking Act is reintroduced to Congress, promising brighter prospects for marijuana stocks and ETFs.
Cannabis ETFs Trending Up to Start Q4
by Sweta Killa
Cannabis stocks and ETFs gained momentum to start the fourth quarter thanks to President Joe's announcement of a historic marijuana reform.
Top and Flop ETFs of Nine Months of 2022
by Sweta Killa
We have highlighted the three ETFs each from the best and worst-performing zones of the nine months of 2022.
Top & Flop Zones of First Half 2022 and Their ETF
by Sweta Killa
The first half of 2022 has been extremely challenging for the global stock market. We have highlighted the three ETFs each from the best and worst-performing zones of first-half 2022.
Roundhill's Cannabis ETF (WEED) Launch Seems Timely
by Sanghamitra Saha
Roundhill Investments recently announced the launch of its own cannabis ETF, namely Roundhill Cannabis ETF (WEED).
Cannabis ETFs Set to Soar on Passage of Legalization Bill
by Sweta Killa
Cannabis stocks are poised to surge further especially following the legislation passed by the House to legalize marijuana nationwide.
After a Downbeat 2021, Will Marijuana ETFs Rebound in 2022?
by Sanghamitra Saha
Cannabis stocks and ETFs were massively downbeat in 2021. However, strong sales backdrop, growing medical usage and still-alive chances of a federal approval may cause a bounce back in pot ETFs in 2022.
Cannabis ETFs Soar on Republican-Led Legalization Bill
by Sweta Killa
Cannabis ETFs have gained momentum lately following the reports of a Republican-led bill, which is seeking to legalize marijuana at the federal level in the United States.
Marijuana Secures Top-Performing ETF Spot Last Week
by Sanghamitra Saha
Wall Street was downbeat last week as a strong rally in the main indexes paused due to a high inflation.
Cannabis ETFs to Surge on Banking Bill Approval in House
by Sanghamitra Saha
On Apr 19, the U.S. House of Representatives okayed legislation that would allow banks to provide services to cannabis companies in states where it is legal.
Cannabis On a Roll: Guide to ETF Investing
by Sanghamitra Saha
Shares of cannabis-related stocks and ETFs continue to be in good shape after a solid run last year.
Should You Invest in Marijuana Stocks & ETFs Now?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.
Cannabis ETFs Spike on Jazz-GW Pharma Deal
by Sweta Killa
Jazz Pharmaceuticals (JAZZ) agreed to buy cannabinoid drug company GW Pharmaceuticals (GWPH) for $7.2 billion in cash and stock that has strengthened the bullish case for the cannabis industry.
4 Best Investing Areas of Q4 & Their Top ETFs
by Sanghamitra Saha
Despite yearlong COVID-19 fears, Wall Street is ending the fourth quarter on a sweet note.
Top 4 ETF Areas of Last Week
by Sanghamitra Saha
Wall Street came up with a mixed performance last week.
ETFs to Buy as Tilray-Aphria Merger Creates Cannabis Giant
by Sweta Killa
Investors seeking to take advantage of the merger deal between Tilray and Aphria could invest in any of the cannabis ETFs.
Cannabis ETFs Set to Soar in 2021 on More U.S. Legalization
by Sweta Killa
Given the prospect of loosening regulations and increased legalization, cannabis stocks are set to soar in 2021.
Why Cannabis Stocks & ETFs Are Soaring
by Sanghamitra Saha
Cannabis stocks and the ETFs have surged lately on hopes of the legalization of marijuana at the federal level under Biden presidency.